Research & Development
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas
3 August 2026 - Zai Lab Limited (NASDAQ:ZLAB) (HKEX:9688), a research-based, commercial-stage biopharmaceutical company based in China and the United States, announced on Monday that the US Food and D...
Biocon launches Yesafili biosimilar in US ophthalmology market
3 August 2026 - Biopharmaceutical company Biocon Limited (BSE:532523) (NSE:BIOCON) announced on Monday the US commercial launch of Yesafili (aflibercept-jbvf), an FDA-approved interchangeable biosimil...
Ractigen Therapeutics IND application for RAG-1C receives FDA clearance
3 August 2026 - Ractigen Therapeutics, a clinical-stage biopharmaceutical company focused on small activating RNA (saRNA) therapeutics, announced on Friday that the US Food and Drug Administration (FD...
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
30 July 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday announced positive topline results from two Phase 3 trials evaluating LITFULO (ritlecitinib) as a potential oral systemic ...
European Commission approves RINVOQ for severe alopecia areata
29 July 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Wednesday it has received European Commission approval for RINVOQ (upadacitinib) to treat adults and adolescents aged 12 and ove...
Incyte's Opzelura approved in European Union for moderate atopic dermatitis
29 July 2026 - Biopharmaceutical company Incyte (Nasdaq:INCY) announced on Wednesday that the European Commission has approved Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis w...